scholarly journals Acquired factor X deficiency in a patient with multiple myeloma: a rare case highlighting the significance of comprehensive evaluation and the need for antimyeloma therapy for bleeding diathesis

2019 ◽  
Vol 12 (9) ◽  
pp. e230249
Author(s):  
Samuel Benjamin Reynolds ◽  
Dhaval Pravinkumar Maghavani ◽  
Hamza Hashmi

Factor X deficiency is a rare bleeding disorder that can be associated with life-threatening bleeding events. Factor X deficiency can either be inherited or acquired. Acquired cases of factor X deficiency can be seen in patients with plasma cell dyscrasias as well as amyloidosis. Coagulopathy, with clinically relevant bleeding events, although rare, is not an unusual phenomenon for patients with systemic amyloidosis. However, clinically relevant bleeding in patients with symptomatic multiple myeloma, without associated amyloidosis, has not been reported in literature before. We present a rare case of multiple myeloma without concomitant amyloidosis that presented with life-threatening bleeding from acquired deficiency of factor X and responded remarkably to treatment for underlying multiple myeloma. This case not only highlights the diagnostic workup required in patients with factor X deficiency but also provides the principles of management of acquired coagulopathy in plasma cell dyscrasias.

2021 ◽  
Vol 2021 ◽  
pp. 1-3
Author(s):  
Ayrton Bangolo ◽  
Trupti Waykole ◽  
Bilal Niazi ◽  
Chandini Sajja ◽  
Mahabuba Akhter ◽  
...  

Factor X deficiency is a rare coagulopathy that can be inherited or acquired. Acquired factor X deficiency has been associated with plasma cell dyscrasias, amyloids, and use of vitamin K antagonists. Of plasma cell dyscrasias, most cases in the literature have been associated with multiple myeloma with or without concomitant AL amyloidosis. Here, we present a rare case of acquired isolated factor X deficiency in an elderly patient with immunoglobulin A (Ig A) monoclonal gammopathy of undetermined significance (MGUS). Herein, we highlight a rare cause of acquired factor X deficiency, and we hope to contribute to the growing literature of plasma cell dyscrasias associated with factor X deficiency.


Author(s):  
Noopur Raje ◽  
Kenneth C. Anderson ◽  
David M. Dorfman ◽  
Arthur T. Skarin

2019 ◽  
Vol 11 ◽  
pp. 251584141882044 ◽  
Author(s):  
Constantine D. Georgakopoulos ◽  
Panagiotis Plotas ◽  
Angelos Angelakis ◽  
Konstantinos Kagkelaris ◽  
Evangelia Tzouvara ◽  
...  

Background:We describe a case where hyperviscosity retinopathy and immunogammopathy maculopathy were the presenting features of IgA multiple myeloma and report the response of maculopathy to intravitreal injection of dexamethasone implants.Case presentation:A 56-year-old man presented at the Department of Ophthalmology with the chief complain of reduced vision for the past 10 days in both eyes. Ophthalmic examination revealed central retinal vein occlusion resembling signs with severe macular edema in both eyes with prominent serous macular detachment. After comprehensive evaluation, an IgA type kappa multiple myeloma was diagnosed complicated with hyperviscosity-associated retinopathy and immunogammopathy maculopathy. Patient was treated with multiple sessions of plasmapheresis, systemic chemotherapy, and finally intravitreal implants of dexamethasone with complete restoration of macular edema and serous macular detachment in both eyes. The visual function and the hyperviscosity-associated retinopathy were partially restored.Conclusion:Ocular manifestation might be the only presenting sign of a life-threatening disease such as IgA multiple myeloma. A high level of suspicion is required to diagnose and treat such cases promptly and effectively.


JAMA ◽  
1987 ◽  
Vol 258 (20) ◽  
pp. 2930 ◽  
Author(s):  
Elliott F. Osserman

JAMA ◽  
1987 ◽  
Vol 258 (20) ◽  
pp. 2930-2937 ◽  
Author(s):  
E. F. Osserman

Cells ◽  
2020 ◽  
Vol 9 (3) ◽  
pp. 768 ◽  
Author(s):  
Renato Zambello ◽  
Gregorio Barilà ◽  
Sabrina Manni ◽  
Francesco Piazza ◽  
Gianpietro Semenzato

Immunotherapy represents a promising new avenue for the treatment of multiple myeloma (MM) patients, particularly with the availability of Monoclonal Antibodies (mAbs) as anti-CD38 Daratumumab and Isatuximab and anti-SLAM-F7 Elotuzumab. Although a clear NK activation has been demonstrated for Elotuzumab, the effect of anti-CD38 mAbs on NK system is controversial. As a matter of fact, an initial reduction of NK cells number characterizes Daratumumab therapy, limiting the potential role of this subset on myeloma immunotherapy. In this paper we discuss the role of NK cells along with anti-CD38 therapy and their implication in plasma cell dyscrasias, showing that mechanisms triggered by anti-CD38 mAbs ultimately lead to the activation of the immune system against myeloma cell growth.


2018 ◽  
Vol 2018 ◽  
pp. 1-5
Author(s):  
A. Raissi ◽  
Z. Chahbi ◽  
M. Zyani ◽  
Y. Darouassi

Multiple myeloma is a plasma cell dyscrasis characterized by mature B cells proliferation in the bone marrow. In rare cases, the disease can present as an extramedullary location, making diagnosis and management more challenging. Here, we describe a rare case of tongue extramedullary myeloma and discuss diagnostic, prognostic, and therapeutic issues.


Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 3650-3650
Author(s):  
Elizabeth M. Blanchard ◽  
Elizabeth Lawler ◽  
Mary Brophy ◽  
Louis Fiore ◽  
Nikhil C. Munshi

Abstract Background: It has been hypothesized that chronic antigenic stimulation in response to chronic inflammation or infection may predispose to the development of plasma cell dyscrasias (PCD) including multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS). Using Department of Veterans Affairs (VA) administrative databases we explored associations between PCD and chronic inflammatory diseases (CID) including rheumatoid arthritis (RA), inflammatory bowel diseases (IBD), psoriasis, asthma, the chronic infections hepatitis C (HEPC) and hepatitis B (HEPB), as well as history of agent orange exposure (AO). Methods: To identify a source population of veterans who are regular users of the VA system for medical care, we gathered data on patients seen in the inpatient or outpatient setting with a diagnosis of hypertension (HTN), diabetes (DM) or coronary artery disease (CAD) between Oct 1, 1996 and Sept 30, 2003. This source population represents more than 70% of all users of the VA healthcare system. Within this population, we identified from ICD-9 codes all prevalent cases of PCD inclusive of MM and MGUS and also current diagnoses of RA, HEPB, HEPC, IBD, psoriasis and asthma. Agent Orange (AO) exposure was ascertained through administrative records. Crude and age-adjusted prevalence odds ratios for associations with PCD are reported. Results: The source population consisted of 4,050,741 veterans who visited the VA Healthcare System nationwide during this time period. Of these patients, 12,936 (0.32%) carried a diagnosis of PCD, including either multiple myeloma or MGUS or both. Odds ratios are presented in Table I. Table I: Associations of Plasma Cell Dyscrasias and Inflammatory Conditions Chronic Condition # of cases Crude OR (95% CI) Age-adjusted OR (95% CI) RA 92511 2.20 (2.03,2.39) 2.15 (1.98,2.32) Hepatitis B 22958 2.03 (1.72,2.38) 3.07 (2.60,3.61) Hepatitis C 116615 1.40 (1.28,1.53) 2.326 (2.12,2.55) IBD 2675 2.83 (1.89,4.23) 3.26 (2.18,4.87) Asthma 183753 1.19 (1.10,1.29) 1.30 (1.20,1.40) Psoriasis 76697 1.43 (1.29,1.59) 1.42 (1.28,1.58) BPH 989271 1.81 (1.75,1.88) 1.53 (1.47,1.58) Agent Orange 69710 1.62 (1.45,1.80) 2.37 (2.07,2.58) Conclusions: We have identified strong associations (OR > 2) between plasma cell dyscrasias and inflammatory conditions including rheumatoid arthritis, IBD and the chronic infections hepatitis B and C. Agent Orange exposure (already known to be associated with plasma cell dyscrasias) served as the positive control and had an age adjusted OR of 2.37. We suspect that residual confounding may be responsible for what appears to be a weak association with benign prostatic hypertrophy (BPH). Asthma and psoriasis do not appear to have a strong association with the development of plasma cell dyscrasias. A detailed ethnic and age adjusted analysis that includes other inflammatory and non-inflammatory conditions is underway in an effort to identify other associations. This study provides a basis for future research efforts focused on identifying cytokine pathways that may link these disorders and subsequently serve as targets for novel interventions to prevent the development or progression of plasma cell dyscrasias.


Sign in / Sign up

Export Citation Format

Share Document